NTRK Gene Fusions: Finding the "Golden Ticket" in Oncology

Christina T. Loguidice
Published: Thursday, Jul 18, 2019
Dr. Benjamin P. Levy

Benjamin P. Levy, MD
Understanding the molecular mechanisms that drive each patient’s cancer is becoming increasingly important to better tailor care as more highly effective agents targeting specific actionable biomarkers are developed and brought to market. These emerging precision agents include tropomyosin receptor kinase (TRK) inhibitors, a class that has been shown to be highly effective in patients with NTRK gene fusions.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication